Cosmo Pharmaceuticals N.V. Aktie

Cosmo Pharmaceuticals N.V. operates as a specialized biopharmaceutical firm, primarily focused on the global development and commercialization of treatments and diagnostic tools within the gastroenterology and endoscopy fields. Its product lineup includes oral tablet formulations like Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, which are prescribed to achieve remission in cases of active, mild to moderate ulcerative colitis. The company also pioneers innovative diagnostic solutions such as GI Genius, an artificial intelligence-driven system designed to enhance the detection of colorectal polyps, and Methylene Blue MMX, a diagnostic drug that improves the visibility of pre-cancerous and cancerous colorectal lesions during colonoscopy procedures. For gastrointestinal endoscopic interventions, Cosmo provides Eleview, an injectable composition used to facilitate the submucosal lift of polyps, adenomas, early-stage cancers, and other mucosal lesions. Beyond its core GI offerings, the company's portfolio extends to Aemcolo/Relafalk, a pharmaceutical indicated for traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth. In the dermatological space, it offers Winlevi, an androgen receptor inhibitor for the treatment of acne vulgaris. Further developments encompass Clascoterone, another androgen receptor inhibitor targeting androgenetic alopecia on the scalp; Rifamycin for irritable bowel syndrome with diarrhea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent employed for procedural sedation; CB-03-10, an oral androgen receptor antagonist under investigation for solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a unique single-use enema formulation. Cosmo Pharmaceuticals N.V. has established licensing agreements with partners including RedHill Biopharma Ltd. and Acacia Pharma Group plc. The company was founded in 1997 and its corporate headquarters are located in Dublin, Ireland.